Verona puts COPD candidate RPL544 in focus for 2017, NASDAQ in four months?

According to Verona Pharma’s CEO, Dr. Jan-Anders Karlsson, the highlights of 2016 were encouraging clinical data for RPL554, additional financing from “a very experienced syndicate” of investors, and further strengthening of the company’s Board and executive team.

Advancing RPL554 in the second phase will be in the focus for 2017, as well as plans for a NASDAQ IPO.

The company’s loss after tax was £5.02 million, compared to £7.49 million in 2015. Verona said that such result is reflecting tight cost control and a lower level of R&D spend especially on clinical studies during the year.

Verona has also announced plans to register initial public offering in the United States. However, it hasn’t decided yet on the number of shares and price of the proposed offering. The proposed offering is expected to begin in next four months.